FDA’s own former acting commissioner warns reclassifying 14 unapproved peptides would undo six decades of drug-testing requirements. Meanwhile, a startup found 30% of consumer peptides are mislabeled or contaminated.
image from grok
RFK Jr., now heading the FDA, plans to reclassify roughly 14 peptide drugs within weeks, reversing a 2023 safety-driven removal from compounding pharmacy permits. These peptides—including BPC-157, CJC-1295, and AOD-9604—are marketed for weight loss, muscle-building, and anti-aging despite experts calling the evidence base "woefully minuscule" and "100 percent bro science." Scientists warn that potential cancer risks from growth-promoting peptides may take 3-5 years or longer to manifest, raising concerns about moving forward without adequate safety monitoring.
Robert F. Kennedy Jr. has spent years arguing that the Food and Drug Administration serves pharmaceutical interests instead of the public. He now leads the agency. He wants to make it easier to buy a class of drugs with minimal evidence they work and uncertain evidence they don't cause harm.
In an interview on Joe Rogan's podcast, Kennedy said he expected the FDA to reclassify roughly 14 peptide drugs within weeks, reversing a 2023 decision that had removed them from a list of compounds compounding pharmacies were permitted to produce. Compounding pharmacies customize medications for individual patients — a workaround for people who need formulations not sold by commercial manufacturers. The 2023 action, which the FDA said was driven by safety concerns, removed 19 peptides from that list, ProPublica reported. NPR reported that Kennedy called that move illegal, arguing the FDA has no authority to restrict drugs on efficacy grounds. He said the agency should only act on safety signals — and claimed none existed.
Peptides are short chains of amino acids, the building blocks of proteins. Some occur naturally in the body; others are synthesized. The ones in question — including BPC-157, CJC-1295, ipamorelin, and AOD-9604 — are marketed for weight loss, muscle-building, anti-aging, tissue repair, and sexual dysfunction. Dr. Noah Raizman, an orthopedic surgeon in the Washington area, was blunt about their evidentiary status. "It is 100 percent bro science," he told the New York Times.
The scientific record is thin. Eric Topol, director of the Scripps Research Translational Institute, wrote in a newsletter that the data on these peptides is "woefully minuscule." Growth hormone-related peptides carry the potential risk of cancer, he noted — not because there's a demonstrated link in humans, but because broadly promoting cell growth is the kind of thing that warrants monitoring. Cancer risk signals, if they emerge at all, may take three to five more years or longer to appear, Paul Knoepfler, a stem cell researcher at UC Davis, told STAT News. The latency between exposure and tumor detection in oncology is notoriously long.
That uncertainty hasn't slowed demand. Imports of peptide compounds from China — where most gray-market versions are manufactured — doubled in the first three quarters of 2025, reaching $328 million, the New York Times reported. Much of it arrives via direct-to-consumer channels, promoted on social media and through wellness clinics that operate in a regulatory gray zone.
Here is the part Kennedy's pitch doesn't address: nobody knows what's in most of what people are injecting.
A startup called Finnrick has been testing peptides sourced from social media and consumer-facing suppliers using high-performance liquid chromatography, a standard laboratory method. Its findings: roughly 30 percent were mislabeled, underdosed, overdosed, or contaminated with toxins or foreign bacteria. NY Mag's Intelligencer documented the company's work. The testing threshold Finnrick uses — 98 percent minimum purity — is widely considered the floor for acceptable quality, according to U.S. Pharmacopeia standards the company cites. The gap between that standard and what's actually in a vial bought online is not theoretical.
In 2025, two women were hospitalized in critical condition after receiving peptide injections at RAADFest, a longevity conference in Las Vegas, ProPublica reported. Studies of six individual peptides — GHRP-2, ibutamoren mesylate, ipamorelin, CJC-1295, AOD-9604, and melanotan II — documented adverse events including death, according to ProPublica's separate investigation into FDA decision-making. The U.S. Anti-Doping Agency banned the wound-healing peptide BPC-157 in 2022, stating it is not approved for human use by any global regulatory authority and may lead to negative health effects.
Janet Woodcock, who served as the FDA's acting commissioner, put the stakes plainly. Reversing the 2023 restriction, she said, would "disrupt the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S." That 1962 law — the Kefauver-Harris Amendment — required drugmakers to demonstrate efficacy in controlled trials before selling a product. It exists because the market, left to itself, will sell you a drug that makes you feel better and may or may not make you live longer, without telling you which.
The counterargument is that the FDA's 2023 move denied access to people who say these compounds help them, produced through a legal channel, for conditions where conventional medicine offers less. Peptide advocates argue the risk is theirs to take. That is a coherent position. What it is not is a position that ignores the risk — it is one that requires knowing what the risk actually is, which is difficult when the vial in your hand may contain something other than what the label says.
What changes if Kennedy's FDA reclassifies those 14 peptides? The direct effect is to expand the compounding pharmacy supply chain — making these compounds easier to obtain through a legal prescriber rather than an online gray market. The indirect effect is to signal that the federal government regards them as safe enough to produce at scale, which is a different claim than "safe enough for a patient with a prescription to try."
The evidence gap is the story. Not whether peptides work — the data is too thin to answer that — but that we are about to dramatically expand access to compounds with uncertain benefit and documented quality control problems, at a moment when the people pushing hardest for that expansion are also the people who have spent years arguing the FDA is too risk-averse. The FDA banned these 19 peptides in 2023 not because they were proven dangerous, but because the quality control problem in the compounding supply chain was bad enough that the agency couldn't sign off on routine production. That problem hasn't been fixed. The imports from China haven't stopped. And the cancer signal, if it's there, is still years from being legible.
Kennedy wants to reclassify roughly 14 peptides in a couple of weeks. The question worth asking is: before or after anyone tests what's in the vials.
Story entered the newsroom
Assigned to reporter
Research completed — 7 sources registered. FDA moving to reclassify ~14 peptides from Category 2 to Category 1, allowing compounding pharmacies to dispense them. In 2023, FDA banned 19 peptides
Draft (987 words)
Reporter revised draft (987 words)
Reporter revised draft (986 words)
Approved for publication
Published (994 words)
Get the best frontier systems analysis delivered weekly. No spam, no fluff.
Biotech & Life Sciences · 1h 39m ago · 2 min read
Biotech & Life Sciences · 1h 41m ago · 3 min read
